us central bank digital currency- Top Knowledge

At present, I am optimistic about tomorrow's trend. It is stronger than expected to maintain this trend today. Although the index has not increased much, the short-term trend at the daily level is still upward, and the quantity can be maintained. Should it continue to rise? The probability of continuing to close up tomorrow is still very high, and the short-term trend of the 60-minute level is to go well again.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".

This is a real long-term positive, which is manifested in three aspects: first, it is conducive to attracting investors to invest in the broad-based index through personal pension accounts; Second, it is helpful to inject new long-term funds into the capital market, optimize the investor structure, stabilize the market and promote the healthy development of the capital market; Third, it reflects the care of the regulatory authorities for the capital market and helps to enhance investors' confidence.This afternoon, the Government of the Hong Kong Special Administrative Region welcomed the passage of the Stamp Duty Legislation (Miscellaneous Amendments) Bill 2024 by the Legislative Council, which exempted the transfer of shares or units of real estate investment trusts and the securities distribution business of option makers, and revised the stamp duty collection arrangements under the paperless securities market system in Hong Kong.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".

Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Shanghai stock exchange recently releasedThere will be no surprises on Thursday!